Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Alcohol Use Disorder (AUD)

Psilocybin for Alcohol Use Disorder (AUD)

46 papers and 18 clinical trials exploring psilocybin as a treatment for alcohol use disorder (aud).

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationOver 100 million cases worldwide, making AUD the most common substance use disorder.

Alcohol Use Disorder (AUD)

Alcohol Use Disorder (AUD) is a prevalent condition characterised by an inability to control alcohol consumption despite adverse consequences. Emerging research indicates that psychedelics may offer promising therapeutic avenues for treating AUD, with various compounds showing potential in clinical trials.

Full Alcohol Use Disorder (AUD) profile

Academic Research

46 papers
Open Accessindividual

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder

This longitudinal randomised study (n=37) in detoxified patients with alcohol use disorder examined DNA methylation changes after psilocybin 25 mg versus placebo and found one psilocybin-linked methylation site, plus broader changes related to depression and drinking measures. The changes involved genes and pathways linked to neuroplasticity and immune function.

Published
May 26, 2026
Journal
Translational Psychiatry
Authors
Urban, M. M., Zillich, L., Rieser, N. M., Herdener, M., Spanagel, R., Vollenweider, F. X., Preller, K. H., Meinhardt, M. W.
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Open Accessindividual

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial

In an open‑label Phase IIa trial (n-12), a single 10 mg intranasal dose of 5‑MeO‑DMT (BPL‑003) given alongside a 10‑week relapse‑prevention CBT programme was acceptable in safety and tolerability in people with moderate–severe alcohol use disorder. Over 12 weeks, participants showed large improvements in drinking (mean abstinent days rose from 33.2% to 80.8% and heavy drinking days fell from 56.2% to 13.2%), providing preliminary evidence of efficacy and supporting larger controlled trials.

Published
December 10, 2025
Journal
Addiction
Authors
Marsden, J., Kelleher, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Roberts, C., Rucker, J. J., Scott, G., Saeger, I., Small, F., Seynaeve, M.
Paywallindividual

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

In this double‑blind, randomised pilot trial of recently detoxified patients with severe alcohol use disorder and comorbid depression, two 25 mg psilocybin‑assisted psychotherapy sessions (versus 1 mg control) were feasible, acceptable and safe. At 12 weeks the 25 mg group showed higher abstinence (55% vs 11%) and significant reductions in percent drinking days and craving frequency, although blinding was imperfect and the study was small and preliminary.

Published
July 24, 2025
Journal
Addiction
Authors
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., Sergent, F.
Open Accessindividual

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial

This randomised, cross-over study (n=7) used precision functional mapping with high-resolution multi-echo fMRI to characterise psilocybin (25mg) versus methylphenidate effects on brain networks, revealing decreased network modularity during psilocybin exposure and reproducible network changes. Participants showed unique brain configurations and reported stronger mystical experiences with psilocybin compared to methylphenidate.

Published
June 5, 2025
Journal
Scientific Data
Authors
Subramanian, S., Renau, R., Perry, D., Chacko, R., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J., Metcalf, N., Lenze, E. J., Snyder, A. Z., Dosenbach, N. U. F., Nicol, G., Siegel, J. S.
Open Accessindividual

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

Published
April 1, 2025
Journal
EClinicalMedicine
Authors
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., Preller, K. H.

Clinical Trials

18 trials
Not yet recruitingPhase II

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

This Phase II, randomized, quadruple‑masked, parallel trial (n=36) will evaluate the safety and preliminary efficacy of psilocybin‑assisted psychotherapy in adults aged 18–65 with severe alcohol use disorder, with primary outcomes including percent heavy drinking days and adverse effects and secondary measures of cue‑induced craving and neural response by fMRI. Participants will be randomised 1:1 to a low‑dose or full‑dose psilocybin arm and will complete two supervised dosing sessions paired with a standardised psychotherapy protocol. Participants in the low‑dose arm receive oral psilocybin capsules of 10 mg at the first session with an optional escalation to 15 mg at the second session; the full‑dose arm receives 30 mg at the first session with an optional escalation to 40 mg at the second session. Dosing sessions occur in a controlled clinical setting four weeks apart with preparatory and integration sessions delivered by a dyad of trained therapists, continuous monitoring during dosing, and support from a peer recovery coach plus optional outpatient addiction treatment. Eligible participants are recruited up to 90 days after completing inpatient withdrawal management; outcomes are assessed through 48 weeks after the second dose, including percent heavy drinking days (weeks 0–24 after the first dose), adverse events at multiple post‑treatment timepoints, cue‑induced craving (baseline, 4 and 24 weeks after the second treatment), and fMRI measures one week before and one week after the second psilocybin session.

Started
May 1, 2026
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT07296094
RecruitingPhase II

Psilocybin with Psychological Support (Psi-PS) for Military Veterans and First Responders with Co-occurring PTSD & Alcohol Use Disorder (AUD) (Psi-PS)

This Phase II, double-blind, placebo-controlled trial (n=40) will investigate the safety, effectiveness, and lasting effects of psilocybin (25mg) combined with psychological support (Psi-PS) in military veterans and first responders with both alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD).

Started
March 1, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06853912
Not yet recruitingPhase II

Psilocybin-assisted Therapy for Alcohol Use Disorder

This double-blind, randomised, Phase II trial (n=90) will evaluate the efficacy of psilocybin-assisted therapy (25 mg x2) versus niacin (250 mg x2) plus therapy to reduce heavy drinking days in people with Alcohol Use Disorder.

Started
September 1, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06444243
RecruitingPhase II

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

This double-blind, randomized, placebo-controlled Phase II trial (n=200) investigates the therapeutic neural mechanisms of psilocybin (30mg) in patients with alcohol use disorder (AUD).

Started
July 1, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06349083
RecruitingPhase II

Psilocybin vs Ketamine for Alcohol Use Disorder (Psi vs Ket)

Double-blind, randomised, active-comparator trial (n=80) comparing single-dose psilocybin (30 mg) versus weight-based ketamine (0.75 mg/kg) with psychotherapy in adults with moderate–severe AUD.

Started
June 1, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06405607
Active not recruitingPhase II

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

Randomized, open-label, active-comparator controlled trial (n=20) comparing psilocybin-assisted psychotherapy (25 mg oral) vs ketamine-assisted psychotherapy (200 mg oral) in males with moderate or severe alcohol use disorder.

Started
February 2, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT05421065

Explore further

Search all Psilocybin papers Search all Alcohol Use Disorder (AUD) trials Full Psilocybin profile Full Alcohol Use Disorder (AUD) profile